Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05468203

PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care (PREVENTS-AKI)

Sponsor: Australian and New Zealand Intensive Care Society Clinical Trials Group

Interventions Dapagliflozin 10mg Tab Placebo

Updated 6 times since 2022 Last updated: Sep 9, 2025 Started: Nov 29, 2023 Primary completion: Aug 31, 2026 Completion: Mar 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acute Kidney Injury, this trial is actively recruiting participants. The trial is conducted by Australian and New Zealand Intensive Care Society Clinical Trials Group and has accumulated 6 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE3
Sep 2024 — Oct 2025 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Jul 2024 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2023 — Jan 2024 [monthly]

Not Yet Recruiting PHASE3

▶ Show 1 earlier version

Sep 2022 — Sep 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Australian and New Zealand Intensive Care Society Clinical Trials Group
The George Institute
University Medical Center Groningen

Data source: The George Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ballarat, Australia
• Heidelberg, Australia